The New York Times Declares "The A.I. Gold Rush Is Upon Us"

Recent articles in The New York Times and other notable publications point to the current flood of investor interest in artificial intelligence platforms. Notable releases of ChatGPT, Microsoft's OpenAI CoPilot and Google's generative AI for its Workspace apps all indicate widespread adoption of next-generation machine learning technologies for an extraordinary breadth of applications.At GATC Health, we are at the forefront of this next wave of Artificial Intelligence to deliver safer, more effective drugs while dramatically reducing costs and time to market for our partners—ultimately improving patient experience and outcomes. It is this specialization that we feel allows us to excel in healthcare even as the tech giants battle for dominance in office and productivity markets. Here is a quick recap of recent pieces from The New York Times:

'Let 1,000 Flowers Bloom’: A.I. Funding Frenzy Escalates

In just weeks, a gold rush into artificial intelligence start-ups has become a full-blown mania.

March 14, 2023 — the New York Times

(https://www.nytimes.com/2023/03/14/technology/ai-funding-boom.html)

We’re Unprepared for the A.I. Gold Rush

Feb. 22, 2023 —The New York Times

(https://www.nytimes.com/2023/02/22/opinion/ai-chatgpt-microsoft-silicon-valley.html)

A New Area of A.I. Booms, Even Amid the Tech Gloom

An investment frenzy over “generative artificial intelligence” has gripped Silicon Valley, as tools that generate text, images and sounds in response to short prompts seize the imagination.

Jan. 7, 2023 — The New York Times

https://www.nytimes.com/2023/01/07/technology/generative-ai-chatgpt-investments.html

About GATC Health

GATC Health Corp is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed and every person’s unique biology is treated with precision.

GATC is accelerating the future of predictive, individualized medicine, today.